- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | XYZ's Square Adds Etra & Cafe Telegrama as Restaurant Momentum Builds | 5 | Zacks | ||
| 21.09. | Electra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.09. | Electra Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.09. | HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt | 732 | anleihencheck.de | Bad Marienberg (www.anleihencheck.de) - HBM Healthcare Investments gibt den erfolgreichen Börsengang ihres Portfoliounternehmens Electra Therapeutics (Nasdaq: ETRA) bekannt. Näheres entnehmen Sie bitte... ► Artikel lesen | |
| 21.09. | HBM Healthcare Investments AG: HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt | 701 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt
21.09.2026 /... ► Artikel lesen | |
| 21.09. | Electra Therapeutics Prices $350 Million In Upsized IPO To Advance Precision Medicines For Immune Diseases And Cancer | 3 | pulse2.com | ||
| 18.09. | Antibody therapy developer Electra Therapeutics upsizes IPO seeking nearly $350M | 4 | Seeking Alpha | ||
| 18.09. | Antibody biotech Electra Therapeutics prices upsized IPO at $15 midpoint | 2 | Renaissance Capital | ||
| ELECTRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.09. | Inflammation biotech Electra Therapeutics charges up with $350M from upsized IPO | 1 | FierceBiotech | ||
| 18.09. | Electra Therapeutics amasses $350M in biotech's latest big IPO | 5 | BioPharma Dive | ||
| 18.09. | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | 353 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| 17.09. | Börsengang von Electra Therapeutics: Preis dürfte über Mitte der Spanne liegen | 1 | Investing.com Deutsch | ||
| 17.09. | Dear Future Electra Therapeutics Stock Fans, Mark Your Calendars for Sept. 18 | 1 | Barchart.com | ||
| 15.09. | Electra Therapeutics targets $342m IPO to fund hyperinflammatory syndrome drug's pivotal trials | 1 | Pharmaceutical Technology | ||
| 15.09. | Electra Therapeutics sets terms for IPO, hoping to raise up to $347m | 3 | pharmaphorum | ||
| 14.09. | Electra Therapeutics aims for $342M IPO to power inflammatory drug's push through phase 3 | 2 | FierceBiotech | ||
| 14.09. | Antibody biotech Electra Therapeutics sets terms for $325 million IPO | 2 | Renaissance Capital | ||
| 14.09. | Electra Therapeutics targets $977.6 million valuation in US IPO | 1 | Reuters | ||
| 14.09. | Electra Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 28.08. | Electra Therapeutics beantragt Börsengang zur Finanzierung von Medikamenten gegen Immunerkrankungen | 6 | Investing.com Deutsch |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| ABSCI | 10,165 | +0,05 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen ELECTRA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,22 % bei einem Aktienkurs von 9,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELECTRA THERAPEUTICS INC finden Sie auf Wallstreet Online.